Truist Financial Corp Cuts Stake in Henry Schein, Inc. (NASDAQ:HSIC)

Truist Financial Corp cut its stake in Henry Schein, Inc. (NASDAQ:HSICGet Rating) by 17.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 11,745 shares of the company’s stock after selling 2,425 shares during the quarter. Truist Financial Corp’s holdings in Henry Schein were worth $773,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in HSIC. Cambridge Investment Research Advisors Inc. increased its position in shares of Henry Schein by 2.4% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 5,262 shares of the company’s stock worth $459,000 after acquiring an additional 122 shares during the last quarter. HighTower Advisors LLC increased its position in shares of Henry Schein by 18.9% during the first quarter. HighTower Advisors LLC now owns 14,030 shares of the company’s stock worth $1,220,000 after acquiring an additional 2,226 shares during the last quarter. MetLife Investment Management LLC increased its position in shares of Henry Schein by 23.2% during the first quarter. MetLife Investment Management LLC now owns 37,733 shares of the company’s stock worth $3,290,000 after acquiring an additional 7,095 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of Henry Schein by 6.6% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,555 shares of the company’s stock worth $1,618,000 after acquiring an additional 1,149 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Henry Schein by 4.1% during the first quarter. Dimensional Fund Advisors LP now owns 1,300,357 shares of the company’s stock worth $113,386,000 after acquiring an additional 51,106 shares during the last quarter. 95.45% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Henry Schein

In other news, CEO Stanley M. Bergman sold 54,216 shares of the business’s stock in a transaction that occurred on Monday, December 12th. The stock was sold at an average price of $81.16, for a total transaction of $4,400,170.56. Following the completion of the transaction, the chief executive officer now directly owns 488,126 shares in the company, valued at $39,616,306.16. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Bradford C. Connett sold 6,840 shares of the business’s stock in a transaction that occurred on Wednesday, December 21st. The stock was sold at an average price of $80.71, for a total transaction of $552,056.40. Following the sale, the chief executive officer now owns 55,412 shares of the company’s stock, valued at $4,472,302.52. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Stanley M. Bergman sold 54,216 shares of the business’s stock in a transaction that occurred on Monday, December 12th. The stock was sold at an average price of $81.16, for a total value of $4,400,170.56. Following the sale, the chief executive officer now directly owns 488,126 shares in the company, valued at approximately $39,616,306.16. The disclosure for this sale can be found here. Over the last three months, insiders sold 76,397 shares of company stock worth $6,190,246. Company insiders own 1.00% of the company’s stock.

Analysts Set New Price Targets

HSIC has been the topic of a number of analyst reports. StockNews.com raised Henry Schein from a “hold” rating to a “buy” rating in a research report on Thursday. William Blair reissued a “market perform” rating on shares of Henry Schein in a report on Tuesday, November 1st. Piper Sandler lowered their price objective on Henry Schein from $96.00 to $85.00 and set an “overweight” rating for the company in a report on Monday, September 26th. Finally, Morgan Stanley lowered their price objective on Henry Schein from $72.00 to $70.00 and set an “underweight” rating for the company in a report on Wednesday, December 21st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $84.44.

Henry Schein Stock Performance

Shares of HSIC stock opened at $80.86 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.84 and a debt-to-equity ratio of 0.22. The business has a 50 day moving average of $80.65 and a two-hundred day moving average of $75.59. Henry Schein, Inc. has a 52 week low of $64.75 and a 52 week high of $92.68. The company has a market cap of $10.96 billion, a P/E ratio of 17.58, a PEG ratio of 2.15 and a beta of 0.82.

Henry Schein (NASDAQ:HSICGet Rating) last issued its earnings results on Tuesday, November 1st. The company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The company had revenue of $3.07 billion during the quarter, compared to the consensus estimate of $3.22 billion. Henry Schein had a return on equity of 15.48% and a net margin of 5.06%. As a group, analysts anticipate that Henry Schein, Inc. will post 4.81 EPS for the current year.

About Henry Schein

(Get Rating)

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Further Reading

Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSICGet Rating).

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.